Accelerate Diagnostics Stock Probability of Future Stock Price Finishing Over 7.50
| AXDX Stock | USD 1.66 0.05 3.11% |
Accelerate |
Accelerate Diagnostics Target Price Odds to finish over 7.50
The tendency of Accelerate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 7.50 or more in 90 days |
| 1.66 | 90 days | 7.50 | close to zero percent |
Based on a normal probability distribution, the odds of Accelerate Diagnostics to move over $ 7.50 or more in 90 days from now is close to zero percent (This Accelerate Diagnostics probability density function shows the probability of Accelerate Stock to fall within a particular range of prices over 90 days) . Probability of Accelerate Diagnostics price to stay between its current price of $ 1.66 and $ 7.50 at the end of the 90-day period is about 76.83 .
Given the investment horizon of 90 days Accelerate Diagnostics has a beta of -0.63. This suggests as returns on the benchmark increase, returns on holding Accelerate Diagnostics are expected to decrease at a much lower rate. During a bear market, however, Accelerate Diagnostics is likely to outperform the market. Additionally Accelerate Diagnostics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Accelerate Diagnostics Price Density |
| Price |
Predictive Modules for Accelerate Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Accelerate Diagnostics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Accelerate Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Accelerate Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Accelerate Diagnostics is not an exception. The market had few large corrections towards the Accelerate Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Accelerate Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Accelerate Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.11 | |
β | Beta against Dow Jones | -0.63 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | -0.07 |
Accelerate Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Accelerate Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Accelerate Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics may become a speculative penny stock | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (61.62 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (40.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Earnings call Accelerate Diagnostics Q3 results and FDA clearances |
Accelerate Diagnostics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Accelerate Stock often depends not only on the future outlook of the current and potential Accelerate Diagnostics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Accelerate Diagnostics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.5 M | |
| Cash And Short Term Investments | 13.2 M |
Accelerate Diagnostics Technical Analysis
Accelerate Diagnostics' future price can be derived by breaking down and analyzing its technical indicators over time. Accelerate Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Accelerate Diagnostics. In general, you should focus on analyzing Accelerate Stock price patterns and their correlations with different microeconomic environments and drivers.
Accelerate Diagnostics Predictive Forecast Models
Accelerate Diagnostics' time-series forecasting models is one of many Accelerate Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Accelerate Diagnostics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Accelerate Diagnostics
Checking the ongoing alerts about Accelerate Diagnostics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Accelerate Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics may become a speculative penny stock | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (61.62 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (40.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Earnings call Accelerate Diagnostics Q3 results and FDA clearances |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.